Clinical Associate Professor
Department of Pharmacy Practice
College of Pharmacy
Oregon Health & Science University
3303 SW Bond Ave., CH12C
Portland, OR 97239
Phone: 503-494-1598
williacr@ohsu.edu
Residency, Cedars-Sinai Medical Center, 1994–1995
Pharm.D., University of California at San Francisco, 1990–1994
Pre-Pharmacy, University of California at Los Angeles, 1987–1990
Assistant Professor of Pharmacy Practice, Purdue University School of Pharmacy, 1995–2002.
Associate Professor of Pharmacy Practice, Purdue University School of Pharmacy, 2002–2006.
Adjunct Associate Professor of Medicine, Indiana Univesity School of Medicine, 2002–2006.
Clinical Associate Professor of Pharmacy Practice, Oregon State University College of Pharmacy, 2006–present.
Clinical Pharmacist, Department of Pharmaceutical Services, Wishard Memorial Hospital, Indianapolis, Indiana, 1995–2006.
Clinical Staff, Wishard Cardiology Clinic, 1998–2006.
American Heart Association, Circulation and Basic Science Council, 1998–present.
Member, Wishard Health Services Pharmacy and Therapeutics Committee, 1999–2006.
Editorial Advisor, Clinical Therapeutics, 1999–2001.
Member, American Society of Health System Pharmacists (ASHP), 1999–2003.
Member, American College of Clinical Pharmacy, 2000–present.
Editorial Advisory Board, Pharmacists Letter, 2001–present.
Chair, Medication Use and Evaluation (MUE) committee, Wishard Health Services, 2001–2006.
Co-chair, Wishard Health Services Pharmacy and Therapeutics Committee, 2003–2006.
Member, Exempt/Expedited Institutional Review Board, Indiana University-Purdue University at Indianapolis (IUPUI), 2003–2006.
Reviewer, Journal of the American Pharmacists Association (JAPhA), 2004–present.
Member, American College of Clinical Pharmacy Case Studies Task Force, 2005–present.
Member, National Lipid Association, 2005–present.
Associate Editor, Diabetes Forecast, 2006–present.
Medical School Grant, Merck Inc., 2002–present
Clinical trial of statins in patients with low HDL cholesterol
Kinetic study of enoxaparin dosing in chronic kidney disease
National Kidney Foundation; Hellman (PI)
2002–2005
Jointly funded by Clarian Health Centers, Pfizer and Sanofi-Aventis to establish city-wide lipid working group in effort to increase collaborative efforts on dyslipidemia in Indianapolis, Indiana
Multi-source Educational Center Grant
2003–2006
3-9% recurring annual salary support for clinical center working on several national, multi-center studies
Asthma Clinical Research Center Grant
2000–2006
Book chapters:
1. Williams CD, Haffner S. Primary and Secondary Prevention: Lipid Outcome Studies in Diabetes. In: Therapy for Diabetes Mellitus and related disorders, 5th Ed., American Diabetes Association, Lebovitz HE (ed.), 2009 pp: 598-607.
2. Williams CD, Fay MA, Pigarelli DL. Chapter 54: Myopathies in Drug Induced Diseases, 2nd Ed. Published by American Society of Health-System Pharmacy. 2009 (in press)
3. Williams C. NSAID-induced ulcer disease. In: Schwinghammer TL, Koehler JM, eds. Pharmacotherapy Casebook: A Patient-Focused Approach. 7th ed. New York: McGraw-Hill, 2008.
4. Williams CD. Controversies in managing cardiovascular disease in patients with chronic kidney disease. Pharmacotherapy Self Assessment Program (PSAP). April, 2007; 6th Ed. Book 2.
5. Schellhase EM, Chen JT, Jordan J, Kania DS, Overholser BR, Shepler BM, Sowinski KM, Williams CD, Pharmacology In: Magee DJ, Zachazewski JE, Quillen WS (eds.). Musculoskeletal Rehabilitation Series, Volume II, Scientific Foundations and Principles of Practice. 2006 2nd Ed. W.B. Saunders, Philadelphia.
6. Williams CD. Progression of kidney disease. Pharmacotherapy Self Assessment Program (PSAP). 2003; Fourth Ed., Book 9:261-297.
Selected Articles:
1. Williams CD. Not so choppy SEAS. J Clin Lipid 2009; 3:11-13
2. Williams CD. Reduction in 10-year risk of major CVD end points (CHD death/nonfatal MI) in major statin trials, or substudies of major trials, in diabetic subjects (n=16,032). Table in Prevention and Management of Diabetes Complications. Diabetes Care 2008;31:S26.
3. Deeg MA, Raikwar NS, Johson C, Williams CD. Statin therapy reduces serum levels of glycosylphosphatidylinositol-specific phospholipase D. Translational Research 2007;150:153-7 (with editorial).
4. Antons, K, Williams C, Baker SK, Phillips PS. Clinical perspectives of statin-induced rhabdomyolysis. American Journal of Medicine 2006;119:400-409.
5. Jacob S, Williams CD, Deeg M. Fenofibrate, simvastatin and rhabdomyolysis. Diabetes Care 2005;28(5):1258
6. Vasavada N, Williams CD, Hellman R. Ethylene glycol intoxication: case report and pharmacokinetic perspectives. Pharmacotherapy 2003;23(12):1652-58.
7. Williams CD, “Amlodipine PREVENTS angina, not atherosclerosis.” Pharmacotherapy 2002;22:400-402.
8. Williams CD, “Potency of inhaled corticosteroid fails to predict reduced Emergency Department visits.” Peer-reviewed research letter Arch Int Med 2003;163:247-249.
9. Williams CD. “Costs and outcomes of switching amlodipine to felodipine” AJHP 2000;57:2287-2288.
10. Williams CD, Wright L. “Osteoarthritis: update on pathology, pathogenesis and treatment.” Journal of Pharmacy Practice 1999 12(4):293-307
